Vimarsana
Biggest News Aggregation in the World

Page 9 - Major Project News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Major Project. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Major Project Today - Breaking & Trending Today

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China - Vimarsana News

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China

Published: July 6, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
United StatesHong KongInnovent BiologicsAscentage PharmaYifan ZhaiPrnewswire Ascentage PharmaElias JabbourEuropean UnionChinese Society Of Clinical OncologyManufacturing ProgramMd Anderson Cancer CenterChina National Medical Products AdministrationDrug AdministrationDana Farber Cancer InstituteNational Reimbursement Drug ListAmerican Society Of HematologyEuropean Medicines AgencyMajor NationalNational Major New Drug DiscoveryDrug EvaluationChinese SocietyClinical OncologyTreatment Hematologic MalignanciesChief Medical OfficerPriority Review
Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential - Vimarsana News

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

Published: June 6, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
Hong KongWestern AustraliaUnited StatesPrnewswire Ascentage PharmaSikander AilamadhiYifan ZhaiAscentage PharmaAmerican Society Of Clinical OncologyChina National Medical Products AdministrationNational Reimbursement Drug ListDana Farber Cancer InstituteMd Anderson Cancer CenterMajor NationalPoster PresentationAmerican SocietyClinical OncologyAnnual MeetingPrincipal InvestigatorChief Medical OfficerHematologic MalignanciesChronic LymphocyticMain BoardStock ExchangeHong Kong LimitedMajor National Rd Projects
Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC - Vimarsana News

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Published: June 6, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
United StatesLi ZhangWestern AustraliaHong KongYifan ZhaiAscentage PharmaNational Reimbursement Drug ListAmerican Society Of Clinical OncologySun Yat Sen University Cancer CenterChina National Medical Products AdministrationMajor NationalMd Anderson Cancer CenterDana Farber Cancer InstitutePoster DiscussionAmerican SocietyClinical OncologyPrincipal InvestigatorSun Yat Sen University CancerChief Medical OfficerLung CancerNon Small CellMain BoardStock ExchangeHong Kong LimitedMajor National Rd Projects
American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian - Vimarsana News

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

Published: June 5, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongHagopm KantarjianAscentage PharmaDajun YangDavida KarnofskyDana Farber Cancer InstituteMd Anderson Cancer CenterAmerican Society Of Clinical OncologySamsung Distinguished UniversityDepartment Of LeukemiaRice Baker Institute HoustonSociety Of Hematologic OncologyUniversity Of Texas Md Anderson Cancer CenterMajor NationalNational Reimbursement Drug ListChina National Medical Products AdministrationDrug AdministrationClinical Advisory BoardProf HagopMemorial AwardAmerican SocietyClinical OncologyAnnual MeetingSamsung Distinguished University Chair
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough - Vimarsana News

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough

Published: June 5, 2023

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesWestern AustraliaInnovent BiologicsRuihua XuYifan ZhaiAscentage PharmaAmerican Society Of Clinical OncologyMd Anderson Cancer CenterMajor NationalEuropean UnionDana Farber Cancer InstituteSun Yat Sen University Cancer CenterEuropean Medicines AgencyAmerican Society Of HematologyChina National Medical Products AdministrationNational Major New Drug DiscoveryNational Reimbursement Drug ListChinese Society Of Clinical OncologyManufacturing ProgramDrug AdministrationPoster PresentationAmerican SocietyClinical OncologyBreakthrough Therapy Designation